SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 5, 2018, Pages 349-352

  De Block, Christophe ^a,b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; DULAGLUTIDE; EXENDIN 4; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FUSION PROTEIN; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; SODIUM GLUCOSE COTRANSPORTER 2;

ANTIDIABETIC ACTIVITY; CARDIOVASCULAR EFFECT; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG POTENTIATION; GASTROINTESTINAL TOXICITY; GLUCONEOGENESIS; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRIORITY JOURNAL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; DOUBLE BLIND PROCEDURE;

DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; RECOMBINANT FUSION PROTEINS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85042461496     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(18)30031-7     Document Type: Note

References (11)

1. American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2018. Diabetes Care 41:suppl 1 (2018), S73–S85.
2. Drucker, DJ, The cardiovascular biology of glucagon-like peptide-1. Cell Metab 24 (2016), 15–30.
3. Heerspink, HJL, Perkins, BA, Fitchett, DH, Husain, M, Cherney, DZI, Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134 (2016), 752–772.
4. Muskiet, MHA, Tonneijck, L, Smits, MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol 13 (2017), 605–628.
5. Cefalu, WT, Kaul, S, Gerstein, HC, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 41 (2018), 14–31.
6. Edelman, SV, Polonsky, WH, Type 2 diabetes in the real world: the elusive nature of glycemic control. Diabetes Care 40 (2017), 1425–1432.
7. Frías, JP, Guja, C, Hardy, E, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 4 (2016), 1004–1016.
8. Ludvik, B, Frías, JP, Tinahones, FJ, et al. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol, 2018 published online Feb 23. http://dx.doi.org/10.1016/S2213-8587(18)30023-8.
9. Ferrannini, E, Muscelli, E, Frascerra, S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 124 (2014), 499–508.
10. Montvida, O, Shaw, J, Atherton, JJ, Stringer, F, Paul, SK, Long-term trends in antidiabetes drugs in the US: real-world evidence in patients newly diagnosed with type 2 diabetes. Diabetes Care 41 (2018), 69–78.
11. Ferrannini, E, Mark, M, Mayoux, E, CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39 (2016), 1108–1114.